2017 Virtual Symposium: Closing the Gap Created by Clinical Inertia: New Strategies for T2DM Treatment

The prevalence of T2DM in the United States is 29.1 million and it is the seventh leading cause of death and a major cause of morbidity, including microvascular, macrovascular, cerebrovascular, and peripheral vascular disease complications. Clinicians face several challenges in helping patients with T2DM reach their glycemic goals, including an increasing armamentarium which gives rise to confusion regarding proper selection and sequence, multiple sets of available evidence-based guidelines, and “clinical inertia” – the failure to close the gap between best practice and the patient’s usual level of care. The goal of this symposium is to increase awareness among clinicians of the challenges in reaching T2DM glycemic targets, to review the clinical guidelines for T2DM treatment using an array of antihyperglycemic agents, and to present evidence on emerging basal insulin/GLP-1RA fixed-ratio combination products.

Treatment of T2DM: What do the guidelines tell us?

Presenter: Yehuda Handelsman, MD*

Treatment Intensification: Barriers and Regimens

Presenter: Athena Philis-Tsimikas, MD

Understanding the Titratable Fixed-Ratio Combinations of Basal Insulin and GLP-1 RAs Formulations

Presenter: Julio Rosenstock, MD

Case Study & Discussion

Chairperson: Robert H. Eckel, MD

Presenter: Yehuda Handelsman, MD*Athena Philis-Tsimikas, MDJulio Rosenstock, MD